FDA panel reviewing some peptides to consider loosening regulations for unapproved therapies

The FDA is reviewing seven unapproved peptides to decide whether compounding pharmacies can legally fill prescriptions for them, reversing a Biden-era decision that blocked nearly 20 peptides from compounding. The shift comes amid soaring demand for unproven peptides marketed online for anti-aging and muscle growth, with regulators now facing pressure to legalise supply through licensed doctors rather than the grey market.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.